The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
June 13th 2024
With the new ruling, announced Thursday, the pills will continue to be able to be mailed to patients without an in-person visit with a physician.1
FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
April 4th 2022Axicabtagene ciloleucel (Yescarta) approved for patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
Read More
Data Show Rivaroxaban Lowers Severe Vascular Event Risk in Patients With PAD
April 3rd 2022Results of the phase 3 VOYAGER PAD clinical trial show rivaroxaban (Xarelto; Janssen Pharmaceutical Companies) plus aspirin lowers severe vascular events in patients with peripheral arterial disease after lower-extremity revascularization.
Read More
The Complicated Role of Oncology Pharmacist/Caregiver in Managing Patient Care, Treatment
April 1st 2022Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers that patients with cancer may encounter following their diagnosis.
Watch
Current Guidelines, Appropriate Monitoring Recommendations for Therapies Used in Adult Sarcomas
March 31st 2022Christy S. Harris, PharmD, BCOP, FHOPA, clinical pharmacy specialist at Dana-Farber Cancer Institute, discusses guidelines for common therapies and appropriate monitoring recommendations for selected therapies used in the treatment of adult sarcomas.
Watch
BLA Submitted for Mirvetuximab Soravtansine in Ovarian Cancer
March 30th 2022ImmunoGen, Inc submits Biologics License Application under the accelerated approval pathway for mirvetuximab soravtansine monotherapy for patients with FRα-high platinum-resistant ovarian cancer previously treated with 1 to 3 prior systemic treatments.
Read More
FDA Approves Cabenuva to Treat HIV in Adolescents 12 Years of Age or Older
March 30th 2022FDA approves expanded indication for the treatment of HIV-1 in virologically suppressed adolescents 12 years of age or older, who weigh at least 35 kg, and who are on a stable antiretroviral regimen, with no history of treatment failure or known or suspected resistance to either cabotegravir or rilpivirine.
Read More